
The CHMP backed sintilimab plus chemotherapy in NSCLC; the FDA issued a complete response letter for the regimen in 2022.
David A. Reardon, MD, presents slides, shown at the 2021 American Society of Clinical Oncology Annual Meeting, from the phase 2 NAVIGATE basket trial and the phase 1/2 SCOUT trial in adult and pediatric patients with tropomyosin receptor kinase (TRK) fusion–positive primary central nervous system (CNS) tumors treated with larotrectinib with or without prior therapy.
David A. Reardon, MD, discusses data from the following presentation:






